6-ECDCA

Specifications / Handling

More Information
Product Details
Synonyms	6α-Ethyl-chenodeoxycholic acid; 6-α-ECDC; Obeticholic acid; INT-747; OCA
Product Type	Chemical
Properties
Formula	C₂₆H₄₄O₄
MW	420.6
CAS	459789-99-2
Purity Chemicals	≥95% (NMR)
Appearance	White solid.
Solubility	Soluble in ethanol, methanol, or DMSO. Slightly soluble in water, dichloromethane and acetone.
Identity	Identity determined by ¹H-NMR.
InChi Key	ZXERDUOLZKYMJM-AMGBFIHRSA-N
Smiles	[H][C@@]12C[C@H](O)CC[C@]1(C)C1CC[C@]3(C)[C@H](CCC3C1[C@H](O)[C@@H]2CC)[C@H](C)CCC(O)=O
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Potent and selective farnesoid X receptor FXR agonist (EC₅₀= 99nM) [1].
Induces SHP in HSCs to suppress TIMP-1 expression [2].
Apoptosis inducer [2].
Protects against liver fibrosis development in rat in vivo [2].
Displays anticholeretic activity in rat in vivo [3].
Promotes preadipocyte differentiation [4].
Regulates adipogenesis and insulin signaling in vivo [4].
Inhibits vascular smooth muscle cell inflammation and migration [5].

Product References

6r-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity: R. Pellicciari, et al.; J. Med. Chem. 45, 3569 (2002)
A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis: S. Fiorucci, et al.; J. Pharmacol. Exp. Ther. 314, 584 (2005)
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis: S. Fiorucci, et al.; J. Pharmacol. Exp. Ther. 313, 604 (2005)
The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo: G. Rizzo, et al.; Mol. Pharmacol. 70, 1164 (2006)
Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration: Y.T. Li, et al.; Arterioscler. Thromb. Vasc. Biol. 27, 2606 (2007)
Pharmacotoxicology of clinically-relevant concentrations of Obeticholic Acid in an organotypic human hepatocyte system: A. Dash, et al.; Toxicol. in vitro 39, 93 (2017)
Computational discovery and experimental verification of farnesoid X receptor agonist auraptene to protect against cholestatic liver injury: X. Gao, et al.; Biochem. Pharmacol. 146, 127 (2017)
Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro: X. Gao, et al.; Toxicol. Appl. Pharmacol., 348, 105 (2018)

Call	+41 61 926 6040
Fax	+41 61 926 6049